LRRK2 aggravates kidney injury through promoting MFN2 degradation and abnormal mitochondrial integrity

Shun Zhang,Subo Qian,Hailong Liu,Ding Xu,Weimin Xia,Huangqi Duan,Chen Wang,Shenggen Yu,Yingying Chen,Ping Ji,Shujun Wang,Xingang Cui,Ying Wang,Haibo Shen
DOI: https://doi.org/10.1016/j.redox.2023.102860
IF: 11.4
2023-08-23
Redox Biology
Abstract:Mitochondrial dysfunction is one of the key features of acute kidney injury (AKI) and associated fibrosis. Leucine-rich repeat kinase 2 (LRRK2) is highly expressed in kidneys and regulates mitochondrial homeostasis. How it functions in AKI is unclear. Herein we reported that LRRK2 was dramatically downregulated in AKI kidneys. Lrrk2 −/− mice exhibited less severity of AKI when compared to wild-type counterparts with less mitochondrial fragmentation and decreased reactive oxygen species (ROS) production in proximal renal tubular cells (PTCs) due to mitofusin 2 (MFN2) accumulation. Overexpression of LRRK2 in human PTC cell lines promoted LRRK2-MKK4/JNK-dependent phosphorylation of MFN2 Ser27 and subsequently ubiquitination-mediated MFN2 degradation, which in turn exaggerated mitochondrial damage upon ischemia/reperfusion (I/R) mimicry treatment. Lrrk2 deficiency also alleviated AKI-to-chronic kidney disease (CKD) transition with less fibrosis. In vivo pretreatment of LRRK2 inhibitors attenuated the severity of AKI as well as CKD, potentiating LRRK2 as a novel target to alleviate AKI and fibrosis.
biochemistry & molecular biology
What problem does this paper attempt to address?